Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun Taps Mitsubishi For Ex-Novartis Japan Portfolio

Executive Summary

Sun has now found a commercial partner in Japan for a bundle of mature products the Indian firm acquired from Novartis earlier this year, in an alliance expected to rapidly boost its presence in this key market and which some say might be expanded.

You may also be interested in...



Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun

With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.

Astellas Offloads Japan Product Basket To Private Equity Group

Astellas has joined the growing ranks of research-based pharma firms offloading their older products in Japan, amid rising pricing and generic pressures and an increasing desire to focus on innovation.

Sun Acquires Novartis Cancer Drug In Specialty Push

Sun Pharmaceutical Industries Ltd, India’s biggest drug firm, has struck a $175m deal to buy the branded skin cancer drug Odomzo from Novartis, continuing a drive to bulk up on higher-margin specialty products in the face of stiff pricing pressure on the generic front.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel